Prostate Cancer Daily

July 13, 2026

Videos

Peer-to-Peer Clinical Conversations

Comparing Piflufolastat and Flotufolastat Urinary Excretion and Detection Rates in Recurrent Prostate Cancer - Brian Helfand

Brian Helfand

Brian Helfand presents a prospective intra-patient comparison of flotufolastat and piflufolastat PSMA PET tracers, enrolling 55 post-prostatectomy patients with biochemical recurrence.

View

Managing Low-Volume Metachronous Metastatic Hormone-Sensitive Prostate Cancer - Pedro Barata

Pedro Barata

Pedro Barata discusses systemic therapy selection and monitoring in low-volume metachronous metastatic hormone-sensitive prostate cancer.

View

Beyond the Abstracts

Aglatimagene Besadenovec (CAN-2409) with Radiotherapy for Patients with Localised Prostate Cancer: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial - Beyond the Abstract

ESUR: Opportunities for PSMA-PET/CT and Whole-Body MRI in Advanced Prostate Cancer - Beyond the Abstract

Conference Coverage

ASCO 2026: Discussant – Switching Gears: Tuning the Targeting Moiety of PSMA Directed Radioligand Therapy

ASCO 2026: Real-World Overall Survival Outcomes of Lutetium (Lu177) Vipivotide Tetraxetan Treatment in Prostate Cancer

AUA 2026: Long-Term Oncological Outcomes of Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-Risk Prostate Cancer: Phase 3 Randomized Controlled Trial

PSMA and Beyond 2026: Clinical Trial Updates: PEACE-6 PR Trial

EAU 2026: DISSECTION 2.0 – Extended Pelvic Lymph Node Dissection versus No Pelvic Lymph Node Dissection at Radical Prostatectomy in PSMA PET Negative Staged Men: A Multicenter, Randomized Phase III Trial

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

The performance of prostate-specific antigen density in long-term prostate cancer-mortality risk prediction.

Impact of number of bone metastases on cancer control outcomes in mHSPC, independent of the axial-skeleton CHAARTED definition.

Dosimetric analysis of post-radiotherapy sexual dysfunction in patients receiving definitive stereotactic body radiotherapy (SBRT) for prostate cancer: a secondary analysis of MIRAGE.

68Ga-PSMA PET/CT in biochemically recurrent prostate cancer: association with genomic data.

Novel Risk Scoring System for Patients with Metastatic Castration Resistant Prostate Cancer Treated with Lutetium-177-PSMA-617.

No racial disparities in prostate cancer-specific mortality after biochemical recurrence following radical prostatectomy or radiation therapy.

Real-world clinical outcomes, genetic testing patterns, and treatment patterns of patients with metastatic castration-resistant prostate cancer treated with olaparib monotherapy in the United States.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Prostate Cancer Daily

Prostate Cancer

Login